Pharmaceuticals

INT'L GROUP

INT'L GROUP released FY2026 Q1 earnings on April 27 After-Market (BJT), actual revenue CNY 8.595 B, actual EPS CNY 0.1361

INT'L GROUP released FY2025 earnings on April 22 After-Market (BJT), actual revenue CNY 33.68 B, actual EPS CNY 0.94

INT'L GROUP released FY2025 Q4 earnings on April 22 After-Market (BJT), actual revenue CNY 8.717 B, actual EPS CNY 0.337

INT'L GROUP FY2026 Q1 Earnings Release on April 28 After-Market (BJT)

INT'L GROUP to Release FY2025 Earnings on April 23 After-Market (BJT)

INT'L GROUP released FY2025 9 Months Earnings on October 28 After-Market (BJT), actual revenue CNY 24.96 B, actual EPS CNY 0.5863

INT'L GROUP released FY2025 Q3 earnings on October 28 After-Market BJT, actual revenue CNY 8.334 B, actual EPS CNY 0.1375

INT'L GROUP to Release FY2025 Q3 Earnings on October 29 After-Market (BJT)

INT'L GROUP released FY2025 Semi-Annual earnings on August 27 Pre-Market (BJT), actual revenue CNY 16.63 B, actual EPS CNY 0.45

INT'L GROUP released FY2025 Q2 earnings on August 27 Pre-Market BJT, actual revenue CNY 8.192 B, actual EPS CNY 0.2633

INT'L GROUP to Release FY2025 Semi-Annual Earnings on August 28, 2025 (BJT)

Inte Pharmaceutical Participates in Bidding for 100% Equity of Zhejiang HuaTong Pharmaceutical Group

Inte Group's Net Profit Down in Q1 2025

INT'L GROUP released FY2025 Q1 earnings on April 27 After-Market BJT, actual revenue CNY 8.437 B, actual EPS CNY 0.1854

Inter Group's Net Profit Grew by 7.53% in 2024

INT'L GROUP released FY2024 Q4 earnings on April 24 After-Market (BJT), actual revenue CNY 8.575 B, actual EPS CNY 0.3075

INT'L GROUP released FY2024 Annual Earnings on April 24 After-Market BJT, actual revenue CNY 33.35 B, actual EPS CNY 0.96

INT'L GROUP FY2025 Q1 Earnings Release on April 28 After-Market BJT

INT'L GROUP to Release FY2024 Annual Earnings on April 25 After-Market BJT

Zhejiang Yinte Group Signs Strategic Cooperation Agreement with Shanghai Pharmaceutical Group

000950

301126

600829

300937

000411

A-share pharmaceutical commercial stocks continue to decline, with Shuyu Pingmin dropping over 18%. HRPC, DAJIAWEIKANG, INT'L GROUP, and Hezong Medicine Easy-To-Buy Pharmaceutical all fell more than 5%, while Huaren Health, CQP, and Kaikai Industry also followed suit

Wallstreetcn

DAJIAWEIKANG

HRPC

Hezong Medicine Easy-To-Buy Pharmaceutical

600272

000078

002589

Pharmaceutical commercial stocks are repeatedly active, NEPTUNUS has a 6-day consecutive limit-up, Realcan hits the limit-up, HRPC, SHKK, INT'L GROUP, and others follow suit. In news, China's drug price registration system has officially launched

SHKK

NEPTUNUS

Realcan

INT'L GROUP announced that its revenue for the third quarter was 8.334 billion yuan, an increase of 2.05% year-on-year; net profit was 73.9815 million yuan, a decrease of 24.19%. Revenue for the first three quarters was 24.963 billion yuan, an increase of 0.75% year-on-year; net profit was 323 million yuan, a decrease of 9.15%

Zhitong

INT'L GROUP: Net profit for the third quarter was 73.9815 million yuan, a decrease of 24.19%

INT'L GROUP announced that its wholly-owned subsidiary, Zhejiang INT'L Pharmaceutical Co., Ltd., intends to participate in the auction for 100% equity of Huadong Pharmaceutical through the Zhejiang Property Exchange, with a listing reserve price of 369 million yuan. This move aims to enhance the company's market share and industry concentration in Zhejiang Province, strengthen its bargaining power with upstream suppliers, and promote the company's high-quality development

INT'L GROUP plans to participate in the auction for 100% equity of Huatuo Pharmaceutical to enhance market share

000705

002727

000028

The pharmaceutical commercial sector saw a short-term surge, with YIXINTANG hitting the limit up, and Sinopharm Accord, NEPTUNUS, INT'L GROUP, ZHEJIANG ZHENYUAN, CQP, and others all rising

ZHEJIANG ZHENYUAN

YIXINTANG

Sinopharm Accord

The pharmaceutical commercial sector has seen a short-term surge, with YIXINTANG hitting the limit up

According to the Zhitong Finance APP, INT'L GROUP released its Q1 2025 report. In the first quarter, the company achieved operating revenue of 8.437 billion yuan, a year-on-year decrease of 1.87%. The net profit attributable to shareholders of the listed company was 101 million yuan, a year-on-year decrease of 5.70%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 98.678 million yuan, a year-on-year decrease of 4.54%

INT'L GROUP released its first-quarter results, with a net profit attributable to shareholders of 101 million yuan, a year-on-year decrease of 5.70%

INT'L GROUP announced that the operating revenue for 2024 is expected to be 33.352 billion yuan, a year-on-year increase of 4.05%; the net profit attributable to shareholders of the listed company is 526 million yuan, a year-on-year increase of 7.53%. The basic earnings per share is 1.02 yuan/share, a year-on-year decrease of 6.42%. The profit distribution plan approved by the company's board of directors is to distribute a cash dividend of 200 million yuan to all shareholders, with no bonus shares and no capital reserve fund conversion into share capital

INT'L GROUP: Net profit of 526 million yuan in 2024, a year-on-year increase of 7.53%

INT'L GROUP announced that Xu Xie no longer serves as chairman, and the current chairman of INT'L GROUP is Wang Yang. In response to the aforementioned personnel changes, INT'L GROUP stated that Xu Xie previously held the position of chairman concurrently, and after the change, he no longer holds that position. The aforementioned change is a normal personnel adjustment within the group. Additionally, after the change, Xu Xie still serves as the leader in charge of the pharmaceutical sector at the China National Foreign Trade Group

INT'L GROUP responds to the change of chairman

On February 24, 2025, INT'L GROUP held a board meeting and elected Wang Yang as the new chairman, succeeding the resigned Xu Xie. After Xu Xie resigned from all positions, the company's board of directors decided that Wang Yang's term would last until the end of the tenth board's term

INT'L GROUP elects Wang Yang as chairman

According to INT'L GROUP, on December 24th, the groundbreaking ceremony for the Zhejiang INT'L Shitang Pharmaceutical Industrial Park project was successfully held in Gongshu, Hangzhou. The Zhejiang INT'L Shitang Pharmaceutical Industrial Park project covers an area of 79,357 square meters, with a total construction area of 155,931.09 square meters. It is planned to form a comprehensive park that integrates pharmaceutical logistics centers and the big health industry incubation, relying on pharmaceutical circulation operation support and extending upstream and downstream industrial resources, achieving "two industries integration."

Jointown

PKU HEALTHCARE

Bio-S

INT'L GROUP: The groundbreaking ceremony for the Zhejiang INT'L Group Shitang Pharmaceutical Industrial Park project was successfully held

INT'L GROUP(000411.SZ)